SOURCE: TheraBiogen, Inc.

August 25, 2010 08:00 ET

TheraBiogen Announces New Orders for TheraMax™ Cold & Flu Spray Products

MERRITT ISLAND, FL--(Marketwire - August 25, 2010) -  TheraBiogen, Inc. (OTCBB: TRAB) announced today that it has received orders from a major chain of grocery stores in the Mid-Atlantic states and Florida for its new Theramax™ Cold & Flu Relief nasal spray and Theramax™ Allergy Relief nasal spray medications. Both products are made from homeopathic ingredients and are completely zinc free. Theramax™ will be launched in these regions to complement its initial distribution by a major national drug chain, both of which are expected in September. Consumers now will have a new choice for seasonal allergy relief, particularly in southern areas like Florida, as the allergy season there tends to be longer due to the warmer climate. Theramax™ Cold & Flu Relief also will be a product choice available for the upcoming cold and flu season, and Theramax™ Cold & Flu Relief can play an important role in the coming critical flu season. Last year's flu situation made headline news worldwide. TheraBiogen expects to make its Theramax™ products increasingly available nationwide through other retailers as consumers prepare for the fall and winter months.

About TheraBiogen, Inc.

TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in the Company's most recently filed Form 10-K and Form 10-Q reports. The forward looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.

Contact Information

  • Contact information:
    Kelly T. Hickel
    TheraBiogen, Inc.
    Telephone: 646-808-3095
    Email Contact